|
2025
|
Invention
|
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria.
D... |
|
|
Invention
|
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis... |
|
|
Invention
|
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir).
The present in... |
|
|
Invention
|
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences.
Discl... |
|
|
Invention
|
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome.
The... |
|
|
Invention
|
Dystrophin gene exon deletion using engineered nucleases.
The invention relates to the field of ... |
|
2024
|
Invention
|
Genetically-modified cells comprising a modified transferrin gene.
Disclosed herein are engineer... |
|
|
Invention
|
Treatment of retinitis pigmentosa using engineered meganucleases.
Disclosed are recombinant mega... |
|
|
Invention
|
Polypeptide linkers for use in engineered meganucleases. The present disclosure encompasses engin... |
|
|
Invention
|
Engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus g... |
|
|
Invention
|
Engineered meganucleases specific for recognition sequences in the pcsk9 gene.
The present inven... |
|
|
Invention
|
Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t c... |
|
|
Invention
|
Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion di... |
|
|
Invention
|
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in... |
|
|
Invention
|
Muscle-specific expression cassettes. e.g.e.g.e.g., engineered nucleases such as engineered megan... |
|
|
Invention
|
Recognition sequences for i-crei-derived meganucleases and uses thereof.
Methods of cleaving dou... |
|
|
Invention
|
Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia... |
|
|
Invention
|
Optimized engineered meganucleases having specificity for the human t cell receptor alpha constan... |
|
2023
|
Invention
|
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene.... |
|
|
Invention
|
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant re... |
|
|
Invention
|
Co-stimulatory domains for use in genetically-modified cells.
The present disclosure provides no... |
|
|
Invention
|
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences. Disclo... |
|
|
Invention
|
Engineered meganucleases that target human mitochondrial genomes. Disclosed herein are recombinan... |
|
|
Invention
|
Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene... |
|
|
Invention
|
Optimized polynucleotides for protein expression.
A method for expressing and delivering a polyn... |
|
|
Invention
|
Optimized polynucleotides for protein expression. A method for expressing and delivering a polynu... |
|
2022
|
Invention
|
Methods for cancer immunotherapy.
The present invention encompasses methods of cancer immunother... |
|
|
Invention
|
Methods for cancer immunotherapy.
The present disclosure encompasses methods of cancer immunothe... |
|
|
Invention
|
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency.
Disclosed are engineered... |
|
|
Invention
|
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir). The present inv... |
|
|
Invention
|
Optimization of engineered meganucleases for recognition sequences.
The invention provides engin... |
|
|
Invention
|
Engineered meganucleases that target human mitochondrial genomes.
Disclosed herein are recombina... |
|
|
Invention
|
Compositions and methods for generating male sterile plants.
Disclosed herein are recombinant me... |
|
|
Invention
|
Modulation of tgf beta signaling in genetically-modified eukaryotic cells.
The application relat... |
|
|
Invention
|
Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase... |
|
2021
|
G/S
|
Genome editing reagents for research purposes; chemical, biochemical, biotechnological products i... |
|
|
G/S
|
Genome editing reagents (term considered too vague by the
International Bureau - Rule 13 (b) of ... |
|
|
G/S
|
genome editing reagents for research purposes; Chemical, biochemical, biotechnological products i... |
|
|
Invention
|
Lipid nanoparticle compositions.
The present invention provides lipid nanoparticle compositions,... |
|
|
Invention
|
Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene.... |
|
2016
|
G/S
|
Genome editing. |
|
|
G/S
|
Genome editing reagents. |
|
|
G/S
|
Genome editing |
|
|
G/S
|
Genome editing reagents |
